KROS - התחייבויות לטווח ארוך של החברה Keros Therapeutics Inc

Keros Therapeutics (KROS) is developing advanced therapies through partnerships with scientific centers, creating synergy to combat bone pathologies and anemia. Innovative protein modulation and a patent shield ensure high margins. This price chart demonstrates a long-term debt structure, which stands at 0.01. The company's growth relies on the study of tissue regeneration and elatercept test results for pulmonary hypertension.

When selecting an issuer, fundamental multiples must be compared with the debt load to assess the stability of the capital structure. By analyzing the issuer's long-term liabilities, an investor can determine the volume of core borrowings required by Keros Therapeutics (KROS) to finance its TGF-beta platform and diversified pipeline, where the dynamics of debt repayment or accumulation reflect the balance between investment growth and the binary risks of clinical trials.